SNC-Lavalin Gets $62 Mln US Contract To Relocate And Equip U.S. Military Hospital

SNC - Lavalin Group (SNCAF.PK,SNC.TO), a professional services and project management company, Wednesday said it has received a $62 million contract by the U.S. Army Corps of Engineers or USACE to relocate and equip U.S. military hospital.

Under the deal, the company will provide Initial Outfitting & Transition or IO&T Services for the replacement of the General Leonard Wood Army Community Hospital or GLWACH in the state of Missouri.

The company will provide full services to transition around 1,156 staff located in the legacy facility and outlying medical spaces into the newly constructed state-of-the-art GLWCH facility.

The new $302 million GLWACH facility is located at Fort Leonard Wood, MO. The new facility includes a hospital, a foot clinic, central utility plant, emergency back-up generators, five-bay ambulance garage, helipad and support facilities.

The GLWACH replacement is the largest project awarded under the IO&T Multiple Award Task Order Contract (MATOC) MATOC III.

The project, which replaces a 40-year-old facility with a new modern medical campus, is programmed to support 5,700 active-duty military personnel, 20,400 trainees and their families.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT